Matters to be Discussed. Any matter not stipulated in this agreement will be determined from time to time after consultation between Party A and Party B.
Matters to be Discussed. Discussions with employees and, where they choose, their representatives will include, where relevant, discussion of:
Matters to be Discussed. The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement #99000. Contact Person For More Information: Xxxx
Matters to be Discussed. The meeting will convene in closed session from 1–2 p.m. on March 18, 1996. The purpose of this closed session is for the Science and Program Review Work Group to consider Injury Control Research Center grant applications recommended for further consideration by the CDC Injury Research Grant Review Committee. On March 19, 1996, from 8:30
Matters to be Discussed. The Subcommittee will discuss the funding of community-based and extramurual research projects as well as discuss the Subcommittee’s role on issues related to charter renewal. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Ms. Xxxxxx Xxxxxxx, Acting Team Leader, Family and Intimate Violence Prevention Team, Division of Violence Prevention, NCIPC, CDC, 0000 Xxxxxx Xxxxxxx, NE, M/S K60, Atlanta, Georgia 30341–3724, telephone 770/ 488–4410. Dated: February 15, 1996. Xxxxxxx X. Xxxxxxx, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC). [FR Doc. 96–4238 Filed 2–23–95; 8:45 am] BILLING CODE 4163–18–M Request for Nominations of Candidates to Serve on the National Vaccine Advisory Committee, Department of Health and Human Services
Matters to be Discussed. The meeting will include the review, discussion, and evaluation of grant applications to fund two new Prevention Research Centers received in response to Program Announcement #01101.
Matters to be Discussed. The agenda will consist of welcome, introductory comments, followed by discussion of each focus area in sequential plenary sessions lasting about 75 minutes each. The four focus areas are: Surveillance,
Matters to be Discussed. Agenda items will include updates from CDC Director, Xxxxx Xxxxxxx, M.D., Ph.D., followed by committee discussion on strategic thinking about the future of CDC and public health, and on lessons from the Los Angeles measles vaccine study. Agenda items are subject to change as priorities dictate. Contact Person For More Information: Xxxxx Xxx XxXxxxx, Acting Executive Secretary, Advisory Committee to the Director, CDC, 0000 Xxxxxxx Xxxx, NE, M/S D–24, Atlanta, Georgia 30333, telephone 404/ 639–7080. Dated: August 27, 1996. Xxxxxxx X. Xxxxxxx, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC). [FR Doc. 96–22333 Filed 8–30–96; 8:45 am] BILLING CODE 4163–18–M Food and Drug Administration [Docket No. 96E–0102] Determination of Regulatory Review Period for Purposes of Patent Extension; CEDAX®Capsules AGENCY: Food and Drug Administration, HHS. ACTION: Notice.
Matters to be Discussed. If there is no stipulation in this agreement and various provisions regarding the use of this service and a dispute arises, it shall be resolved based on the purpose of this agreement. If you disagree with this agreement and other provisions, the user shall be based on the law. The procedure shall be taken. If you use any other method, including after withdrawal, to slander, slander, harass, junk e-mail, or ask for a reply, we may request a claim for damages.
Matters to be Discussed. The agenda will focus on Addressing Tobacco-related Program Specialist, Office on Smoking and Health, 000 Xxxxxxxxxxxx Xxxxxx, XX., Xxxxx 000X, Xxxxxxxxxx, XX 00000, telephone: (202) 205–8500. Agenda items are subject to change as priorities dictate. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: February 5, 2004. Xxxxx Xxxx, Director, Management Analysis and Service Office, Centers for Disease Control and Prevention. [FR Doc. 04–2971 Filed 2–10–04; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2003N–0456] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Prevention of Medical Gas Mixups at Health Care Facilities AGENCY: Food and Drug Administration, HHS. ACTION: Notice.
